A panel of de novo designed intracellular protein binders that target conserved functional regions of MYC with nanomolar affinity, remodel MYC complexes and interaction networks in cells, suppress proliferation across MYC-dependent cancer models, and are depleted from orthotopic pancreatic tumors in vivo are developed.
Abstract
MYC is one of the most frequently dysregulated oncogenic drivers across many cancers, yet direct therapeutic targeting has remained difficult because its function is mediated by disordered regions and transient protein-protein interactions. Here we design proteins that bind epitopes within regions of MYC whose sequence is conserved between human and mouse, including intrinsically disordered motifs required for oncogenic activity. In vitro, the designs bind MYC with nanomolar affinity and in cells they engage MYC, disrupt interactions with MAX, and remodel MYC-associated protein complexes. Expression of the binders decreases cell proliferation across diverse MYC-dependent hematopoietic, liver, pancreatic, and patient-derived tumor models, and in an orthotopic pancreatic cancer model, binder-expressing tumor cells were selectively depleted. This work establishes de novo protein design as a generalizable strategy to therapeutically target intrinsically disordered transcription factors. One-sentence summary We developed a panel of de novo designed intracellular protein binders that target conserved functional regions of MYC with nanomolar affinity, remodel MYC complexes and interaction networks in cells, suppress proliferation across MYC-dependent cancer models, and are depleted from orthotopic pancreatic tumors in vivo.
MYCN is a member of the MYC family of transcription factors and a potent oncogenic driver across neural crest, neuroectodermal, and neuroendocrine malignancies, including neuroblastoma, where MYCN amplification remains one of the most powerful molecular predictors of treatment failure and poor survival. MYCN has long b...
Kyabeth Torres-rodriguez, Angelle L. Brown, John M. Maris et al.· Cancer Letters· 0 citations
It is demonstrated that the functional output of a scaffold lncRNA is encoded in its sub-domain architecture rather than bulk transcript levels, establishing domain-specific RNA targeting as a tractable strategy to rewire protein turnover pathways for otherwise undruggable oncogenes.
Hagoon Jang, B. K. Suh, Fei-Jie Zhang et al.· Nucleic Acids Research· 0 citations
A key strategy for precision therapy lies in identifying and targeting tumor cell-specific metabolic vulnerabilities to develop effective combination treatments. In this study, we demonstrate that vandetanib, a multi-kinase inhibitor, acts as a potent transcriptional repressor of the serine synthesis pathway (SSP) in...
Yan Zhou, Yin-Yin Xie, Fu-Hui Wang et al.· Cell Death & Disease· 0 citations
Background/Objectives: The c-Myc oncoprotein is a master regulator of cell cycle progression, cellular metabolism, and ribosome biogenesis, and its dysregulation occurs in more than 70% of human malignancies. Its intrinsically disordered structure and absence of deep hydrophobic binding pockets have historically limite...
T. Lupanova, Georgii P. Georgiev, A. S. Sobolev· Pharmaceutics· 0 citations
Transcriptional addiction to the androgen receptor (AR) underlies metastatic castration-resistant prostate cancer1, in which AR maintains oncogenic programs through domain-specific interactions with the acetyltransferases p300 and CBP (collectively p300/CBP)2. Here we describe a novel therapeutic modality, domain-alter...
Jie Luo, Jian-Zhang Yang, J. Tien et al.· Nature· 0 citations
Protein aggregation is increasingly recognized as a fundamental feature of cancer biology, particularly in tumors experiencing chronic proteotoxic stress.
TP53
is one of the most frequently mutated genes in human cancers, and many cancer-associated missense mutations promote p53 misfolding and amyloid-like aggreg...
Su-Jin Lee, Tri Pham, Min-Ju Lee et al.· Cell Death & Disease· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.